Autoantibodies as Biomarkers for Cutaneous Melanoma

This webcast will highlight novel technologies that enable the detection of autoantibodies by screening human serum samples against more than 80% of the human proteome. The presence of autoantibodies may indicate immune recognition of melanoma cells and correlate with disease progression, response to therapy and occurrence of treatment-related side effects. While autoantibody panels could enhance diagnostic accuracy and disease monitoring, challenges remain in standardising these biomarkers due to variability in their data analysis pipeline, immune response variability and specificity concerns. Future research integrating autoantibody profiles with other molecular and imaging biomarkers may improve melanoma detection and patient outcomes.